|
|
|||
|
|||
|
|
|||
|
allergy relief allergies |
|||
|
|
|||
|
|||
![]()
|
|||
|
|
|||
|
allergy relief allergies DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide allergy relief allergies. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water allergy relief allergies. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone allergy relief allergies. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration allergy relief allergies. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide allergy relief allergies.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans allergy relief allergies. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs allergy relief allergies. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness allergy relief allergies. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges allergy relief allergies. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma allergy relief allergies. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma allergy relief allergies. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge allergy relief allergies. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma allergy relief allergies. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma allergy relief allergies. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg allergy relief allergies. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data allergy relief allergies. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% allergy relief allergies. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below allergy relief allergies. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed allergy relief allergies. Elderly: The apparent oral clearance of zafirlukast decreases with age allergy relief allergies. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients allergy relief allergies. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults allergy relief allergies. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects allergy relief allergies. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects allergy relief allergies. Drug-Drug Interactions
|
|||
![]()
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| aallergy relief allergies alllergy relief allergies alllergy relief allergies alleergy relief allergies allerrgy relief allergies allerggy relief allergies allergyy relief allergies allergy relief allergies allergy rrelief allergies allergy reelief allergies allergy rellief allergies allergy reliief allergies allergy relieef allergies allergy relieff allergies allergy relief allergies allergy relief aallergies allergy relief alllergies allergy relief alllergies allergy relief alleergies allergy relief allerrgies allergy relief allerggies allergy relief allergiies allergy relief allergiees allergy relief allergiess llergy relief allergies alergy relief allergies alergy relief allergies allrgy relief allergies allegy relief allergies allery relief allergies allerg relief allergies allergyrelief allergies allergy elief allergies allergy rlief allergies allergy reief allergies allergy relef allergies allergy relif allergies allergy relie allergies allergy reliefallergies allergy relief llergies allergy relief alergies allergy relief alergies allergy relief allrgies allergy relief allegies allergy relief alleries allergy relief allerges allergy relief allergis allergy relief allergie a llergy relief allergies al lergy relief allergies all ergy relief allergies alle rgy relief allergies aller gy relief allergies allerg y relief allergies allergy relief allergies allergy relief allergies allergy r elief allergies allergy re lief allergies allergy rel ief allergies allergy reli ef allergies allergy relie f allergies allergy relief allergies allergy relief allergies allergy relief a llergies allergy relief al lergies allergy relief all ergies allergy relief alle rgies allergy relief aller gies allergy relief allerg ies allergy relief allergi es allergy relief allergie s allergy relief allergies lalergy relief allergies allergy relief allergies alelrgy relief allergies allregy relief allergies allegry relief allergies alleryg relief allergies allerg yrelief allergies allergyr elief allergies allergy erlief allergies allergy rleief allergies allergy reilef allergies allergy releif allergies allergy relife allergies allergy relie fallergies allergy reliefa llergies allergy relief lalergies allergy relief allergies allergy relief alelrgies allergy relief allregies allergy relief allegries allergy relief alleriges allergy relief allergeis allergy relief allergise aallergy relief allergies theallergy relief allergies allergy relief allergies | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |